Dr. Wu is an Associate Professor at the Columbia School of Social Work (CSSW), Associate Director of the CSSW Social Intervention Group (SIG), Co-Director of the HIV Intervention Science Training Program (HISTP), and a Faculty Affiliate of the Columbia University Global Health Research Center of Central Asia.
Dr. Woody, Professor in the Department of Psychiatry at the University of Pennsylvania, has 35 years of experience in specialized research on treatment efficacy in substance abuse. His research has focused on the relationships between participation in treatment for substance use disorders and HIV risk.
Dr. Strathdee, Harold Simon Professor and Chief of the Division of Global Public Health in the Department of Medicine at the University of California San Diego School of Medicine, is an infectious disease epidemiologist who has spent the past two decades focusing on HIV prevention in underserved, marginalized populations in developed and developing countries, including injection drug users, men who have sex with men, and sex workers.
Dr. Merchant is an emergency medicine physician, researcher, and epidemiologist. His research concerns social, behavioral, epidemiologic and health services delivery in the areas of emergency medicine, infectious diseases and public health.
Dr. Mehta’s research focuses on the consequences of injection drug use with a particular focus on HIV and HCV. Within HIV and HCV, her interests are broad, ranging from disease prevention to the clinical consequences of the two infections individually and together, as well as access to care and treatment outcomes for HIV and HCV.
Dr. Lai, Professor of Pathology, Radiology Epidemiology and Medicine at the Johns Hopkins School of Medicine, began his research in HIV/AIDS and STDs in the late 1980s. His research interests include epidemiology, drug abuse, HIV/AIDS, STIs, prevention and intervention, cardiac imaging, preventive cardiology, medical consequences of HIV infection, and international health.
Dr. Kurtz, Professor and Co-director of the Center for Research on Substance Use and Health Disparities at Nova Southeastern University, is the principal investigator of two randomized clinical trials, funded by the National Institute on Drug Abuse, to test the efficacy of novel substance use and sexual risk reduction interventions designed for gay and bisexual men and for young adult polydrug users in the club scene.
Dr. Kirk leads a large multidisciplinary team in a program of epidemiological, clinical, and behavioral research centered in the AIDS Linked to the Intravenous Experience (ALIVE) study. His research primarily focuses on access to and consequences of antiretroviral therapy among HIV-infected injecting drug users (IDUs).
Dr. Hogg, Professor of Health Sciences at Simon Fraser University and a Director of Epidemiology and the Population Health Program at the BC Centre for Excellence in HIV/AIDS in Vancouver Canada, received his training in demography and epidemiology. He is involved in several large-scale HIV treatment cohort studies in Canada, North America and Europe.
Dr. Garfein is an infectious disease epidemiologist and Professor in the UCSD School of Medicine, Division of Global Public Health. He began studying HIV and viral hepatitis among persons who inject drugs (PWID) at Johns Hopkins University, continuing this line of research at the Centers for Disease Control and Prevention (1997–2005), and added an emphasis on tuberculosis after joining the faculty at UCSD in 2005.